{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse:00874:a retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahse%3A00874%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001515,
    "timestamp_received": "2026-11-09T16:13:59.189049Z",
    "timestamp_returned": "2026-11-09T16:13:59.190564Z",
    "trace_id": "d4e2b969-475c-4513-b690-cc487c115047"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hse:00874:a",
      "type": "Indication",
      "description": "Induction of remission in newly diagnosed, previously untreated adult acute lymphoblastic leukaemia (ALL) patients (aged 25-65 years) treated on UKALL14-protocol.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2026-08-02:0",
          "type": "Contribution",
          "description": "Initial curation of into moalmanac-db",
          "date": "2026-08-02",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2025-10-01:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2025-10-01",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00874",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "UKALL14 Phase 1 Standard Induction Therapy. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "UKALL14 Phase 1 Standard Induction Therapy, 2026, version number 1a, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7011/874_UKALL14_Phase_1_Standard_Induction_Therapy.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/7011/874_UKALL14_Phase_1_Standard_Induction_Therapy.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2025-10-01",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2026-02-11",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The Republic of Ireland's Health Service Executive (HSE) has approved UKALL14 phase 1 standard induction therapy as a treatment option for the induction of remission in newly diagnosed, previously untreated adult patients with acute lymphoblastic leukaemia (ALL) patients (aged 25-65 years) treated on UKALL14-protocol. The treatment regimen notes that this is a clinical trial protocol intended for off-trial use, and that rituximab is to be included in CD20 positive patients (defined as >20% positivity). The treatment regimen also defines eligibility criteria as aged >= 25 and <= 65. years old with acute lymphoblastic leukaemia OR >= 19 and <= 65 years old with Philadelphia Chromosome Positive acute lymphoblastic leukaemia. Core treatments constituting the regimen are dexamethasone, daunorubicin, vincristine, and methotrexate, with rituximab to be included for CD20 positive patients, imatinib to be included for Philadelphia chromosome positive patients, or PEG-asparaginase for philadelphia chromosome negative patients.",
          "description": "The description text for all Statements derived from this Indication."
        },
        {
          "name": "reimbursement_scheme",
          "value": "Incomplete Reimbursement",
          "description": "Current scheme used to reimburse indication."
        },
        {
          "name": "reimbursement_comment",
          "value": "Imatinib - CDS; other drugs - N/A",
          "description": "More details about the current reimbursement scheme(s)."
        }
      ]
    }
  ]
}